Neurology:咖啡因能否改善帕金森病患者的运动表现?

2017-11-28 易湛苗 环球医学

据了解,咖啡不止是种提神饮料,经常饮用还能减低罹患一些疾病的可能性。2017年10月,发表在《Neurology》上的一项多中心平行对照试验研究,评估了咖啡因对帕金森病(PD)患者运动表现的改善情况。

据了解,咖啡不止是种提神饮料,经常饮用还能减低罹患一些疾病的可能性。2017年10月,发表在《Neurology》上的一项多中心平行对照试验研究,评估了咖啡因对帕金森病(PD)患者运动表现的改善情况。

方法:在这项多中心平行对照试验中,具有1~8年病程、Hoehn & Yahr分期为1~3期、接受稳定对症治疗的PD患者随机分配到200mg咖啡因BID和相匹配的安慰剂胶囊治疗6~18个月的组中。首要研究问题为6个月时客观运动评分是否不同(运动障碍学会——统一帕金森病评定量表(MDS-UPDRS)-III,I级证据)。次要结局指标包括安全性和耐受性、运动症状(MDS-UPDRS-II)、运动波动、睡眠,非运动症状(MDS-UPDRS-I)、认知(蒙特利尔认知评估量表)和生活质量。

结果:60例患者接受了咖啡因,61例接受了安慰剂。咖啡因的耐受性良好,不良反应的发生率与安慰剂相似。与安慰剂相比,咖啡因治疗的帕金森运动症状(首要结局)无改善(MDS-UPDRS-III评分的组间差异,-0.48(95% CI,-3.21~2.25)分)。相似的,对于次要结局指标,任何时间点的运动体征或运动症状(MDS-UPDRS-II)无改变,生活质量无差异。第一个6个月的嗜睡有轻微的改善,但随着时间衰减。咖啡因治疗的运动障碍有轻微增加(MDS-UPDRS-4.1+4.2高0.25分),咖啡因与较差的认知功能测试评分有相关性(平均蒙特利尔认知评估量表评分比安慰剂差0.66(0.01~1.32))。

结论:咖啡因并未提供PD运动表现的临床重要改善(I级证据)。咖啡因与较低PD风险之间的流行病学关联似乎没有被症状的效果所解释。

证据分类:本研究提供了I级证据表明,PD患者使用咖啡因并未显着改善运动表现

原始出处:
Postuma R, Anang J, Pelletier A, et al.Caffeine as symptomatic treatment for Parkinson disease (Café-PD): A randomized trial.Neurology. 2017 Oct 24;89(17):1795-1803. doi: 10.1212/WNL.0000000000004568. Epub 2017 Sep 27.

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1757412, encodeId=22241e57412a9, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sun Dec 03 04:16:00 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000200, encodeId=814e200020052, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Aug 25 04:16:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263938, encodeId=675a1263938a4, content=<a href='/topic/show?id=62c239e74f2' target=_blank style='color:#2F92EE;'>#咖啡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39774, encryptionId=62c239e74f2, topicName=咖啡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Thu Nov 30 07:16:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573925, encodeId=f99315e392576, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Thu Nov 30 07:16:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265062, encodeId=1ff226506229, content=学习了.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Nov 28 16:23:06 CST 2017, time=2017-11-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1757412, encodeId=22241e57412a9, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sun Dec 03 04:16:00 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000200, encodeId=814e200020052, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Aug 25 04:16:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263938, encodeId=675a1263938a4, content=<a href='/topic/show?id=62c239e74f2' target=_blank style='color:#2F92EE;'>#咖啡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39774, encryptionId=62c239e74f2, topicName=咖啡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Thu Nov 30 07:16:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573925, encodeId=f99315e392576, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Thu Nov 30 07:16:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265062, encodeId=1ff226506229, content=学习了.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Nov 28 16:23:06 CST 2017, time=2017-11-28, status=1, ipAttribution=)]
    2018-08-25 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=1757412, encodeId=22241e57412a9, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sun Dec 03 04:16:00 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000200, encodeId=814e200020052, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Aug 25 04:16:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263938, encodeId=675a1263938a4, content=<a href='/topic/show?id=62c239e74f2' target=_blank style='color:#2F92EE;'>#咖啡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39774, encryptionId=62c239e74f2, topicName=咖啡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Thu Nov 30 07:16:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573925, encodeId=f99315e392576, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Thu Nov 30 07:16:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265062, encodeId=1ff226506229, content=学习了.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Nov 28 16:23:06 CST 2017, time=2017-11-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1757412, encodeId=22241e57412a9, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sun Dec 03 04:16:00 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000200, encodeId=814e200020052, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Aug 25 04:16:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263938, encodeId=675a1263938a4, content=<a href='/topic/show?id=62c239e74f2' target=_blank style='color:#2F92EE;'>#咖啡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39774, encryptionId=62c239e74f2, topicName=咖啡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Thu Nov 30 07:16:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573925, encodeId=f99315e392576, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Thu Nov 30 07:16:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265062, encodeId=1ff226506229, content=学习了.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Nov 28 16:23:06 CST 2017, time=2017-11-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1757412, encodeId=22241e57412a9, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sun Dec 03 04:16:00 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000200, encodeId=814e200020052, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Aug 25 04:16:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263938, encodeId=675a1263938a4, content=<a href='/topic/show?id=62c239e74f2' target=_blank style='color:#2F92EE;'>#咖啡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39774, encryptionId=62c239e74f2, topicName=咖啡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Thu Nov 30 07:16:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573925, encodeId=f99315e392576, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Thu Nov 30 07:16:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265062, encodeId=1ff226506229, content=学习了.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Nov 28 16:23:06 CST 2017, time=2017-11-28, status=1, ipAttribution=)]
    2017-11-28 惠映实验室

    学习了.谢谢.

    0

相关威廉亚洲官网

Hum Reprod:酒精和咖啡因与辅助生殖治疗结局是否相关?

2017年9月,发表在《Hum Reprod》上的一项队列研究,研究了在经历ART的女性中,治疗前摄入酒精和咖啡因与不孕治疗结局的相关性。研究结果表明:不孕治疗开始前一年内低至中度酒精和咖啡因摄入对ART中间或临床结局没有不良作用。

SLEEP:术后疼痛怎么办?研究发现咖啡因的微妙作用!

睡眠对于良好的身心健康至关重要,慢性睡眠不足增加了几种慢性健康问题的风险。

JASN ASN:研究发现咖啡因摄入可延长肾病患者的寿命!

根据将于10月31日至11月5日在洛杉矶新奥尔良Ernest N. Morial会议中心进行并发表在ASN肾脏周的一项研究,咖啡因的摄入可能会延长慢性肾病(CKD)患者的生命。

Mayo Clin Proc:降低全因死亡风险 摄入多少咖啡因为宜?

2017年8月,发表在《Mayo Clin Proc》的一项基于人群的前瞻性队列研究,考察了咖啡因摄入与全因和病因特异性死亡率之间的相关性。

中国科学家发现咖啡因让小鼠瘦身的原理,但还是无法帮你减肥

根据本周《自然-通讯》的一项研究 Caffeine inhibits hypothalamic A1R to excite oxytocin neuron and ameliorate dietary obesity in mice表明,咖啡因通过抑制食欲、增加能量消耗,使肥胖小鼠体重下降。该研究发现了个与这种减肥效应相关的神经结构,从而为认识咖啡因调节能量代谢的机制提供了新的见解。

Oncotarget:去咖啡因的绿茶提取物的长期补充不能改变体重或者腹部肥胖

不断的有证据表明肥胖在前列腺致癌和预后中具有作用,因此,鉴定和继续评估有效的干预措施从而减少高风险人群肥胖十分必要。最近,有研究人员调查了日常去咖啡因绿茶儿茶酚(GTC)(多酚E®(PolyE))的消费对具有高风险前列腺癌男性肥胖生物标记的影响。研究人员设计了一个随机的、双盲的试验,包括了97名被诊断为HGPIN或者ASAP的男性。参试者随机的接受为期1年的GTC(PolyE)(n=49)或者安慰